<DOC>
	<DOCNO>NCT00845858</DOCNO>
	<brief_summary>To evaluate safety effectiveness two dos metoclopramide nasal spray solution , 10 mg 14 mg , compare placebo reduce symptom diabetic gastroparesis .</brief_summary>
	<brief_title>Efficacy Safety Metoclopramide Nasal Spray Solution Diabetic Patients With Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Inclusion Criteria 1 . Male subject nonpregnant , nonlactating female subject age 18 75 year ( inclusive ) 2 . Willing able give write informed consent participate study 3 . Ability read understand English 4 . Diagnosis Type 1 Type 2 diabetes 5 . Diagnosis diabetic gastroparesis previously document 6 . A mean daily GCSIDD score ≥2 ≤4 7 day prior Randomization Visit ( Visit 3 , Day 0 ) 7 . Female subject childbearing potential , define surgically sterile least 2 year postmenopausal , must agree use one follow form contraception Screening last dose study drug : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen , barrier ( condom , diaphragm , cervical cap spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( 6months minimum ) 8 . No clinically significant abnormal finding physical examination , medical history , clinical laboratory result ( exception lipid profile , glucose hemoglobin A1c ) screening , opinion Investigator , would jeopardize safety subject impact validity study result 9 . Willingness discontinue current treatment diabetic gastroparesis avoid medication specify protocol duration study Exclusion Criteria 1 . Gastric bypass gastric banding , gastric pacemaker , postsurgical cause gastroparesis disorder know associated abnormal gastrointestinal motility active gastric ulcer , active duodenal ulcer , active severe gastritis , gastric cancer , amyloidosis , neuromuscular disease ( include Parkinson 's disease ) , collagen vascular disease , alcoholism , uremia , malnutrition , untreated hypothyroidism 2 . A history allergic adverse response , include , limited , acute dystonic reaction tardive dyskinesia metoclopramide comparable similar product 3 . History physical finding suggestive tardive dyskinesia 4 . Currently use unwilling unable stop medication know associated tardive dyskinesia ( See Study Reference Manual ) prior Washout ( Visit 2 ) 5 . History allergy ingredient study drug formulation ; metoclopramide , citric acid , sodium citrate , benzalkonium chloride , EDTA , sorbitol 6 . History organ transplant , chronic pancreatitis , gross malabsorptive syndrome , celiac disease , inflammatory bowel disease 7 . Malignancy ( exception basal cell carcinoma skin ) currently present , initially diagnose recur within 5 year enrollment 8 . History clinically significant renal , hepatic , neurologic , hematologic , oncologic , pulmonary , psychiatric , cardiovascular infectious disease , condition , opinion Investigator , would jeopardize safety subject impact validity study result 9 . Have renal dysfunction calculate creatinine clearance ( CrCl ) &lt; 40 mL/min Screening ( Visit 1 ) 10 . Have hemoglobin A1c &gt; 12.5 % Screening ( Visit 1 ) 11 . Inability unwillingness stop use follow agent 7 day Washout Period ( Day 7 Day 1 ) prior Randomization ( Visit 3 , Day 0 ) refrain use 4week study period ; oral parenteral formulation metoclopramide , domperidone , tricyclic antidepressant , macrolide antibiotic , prokinetic agent , cholinergic agent , agent significant anticholinergic effect , narcotic analgesic , orally administer β agonist , spasmolytic , dopamine agonist , monoamine oxidase inhibitor , herbal supplement , fiber bulk product , laxatives 12 . Use neurotoxin ( e.g. , botulinum type A B ) treatment gastroparesis delay gastric empty within 6 month Screening ( Visit 1 ) 13 . Clinically significant abnormal find QTc interval &gt; 450 millisecond ( msec ) ECGs obtain Screening ( Visit 1 ) OR pre postdose Randomization ( Visit 3 ) 14 . Inability unwillingness stop use medication associate Torsades de Pointes prolong QT interval 30 day prior initial symptom assessment refrain use 4week study period ( see Study Reference Manual ) 15 . Female subject try conceive , pregnant , lactate 16 . Positive serum human chorionic gonadotropin ( HCG ) pregnancy test Screening positive HCG urine test Day 0 prior administration study drug woman childbearing potential 17 . History alcohol drug abuse within year prior Screening Visit , current know evidence substance dependence abuse 18 . Participation clinical ( investigational ) trial receipt nonFDA approve therapy within 30 day prior Screening Visit ( Visit 1 ) exception domperidone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Gastroparesis</keyword>
	<keyword>Diabetic Gastroparesis</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Delayed Gastric Emptying</keyword>
</DOC>